$84.42
+5.86 (+7.46%)
Open$80.26
Previous Close$78.56
Day High$85.74
Day Low$80.00
52W High$90.87
52W Low$14.42
Volume—
Avg Volume1.61M
Market Cap4.01B
P/E Ratio31.18
EPS$2.39
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
-41.0% upside
Current
$84.42
$84.42
Target
$49.81
$49.81
$29.15
$49.81 avg
$64.16
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 363.87M | 344.31M | 329.37M |
| Net Income | -20,456,259 | -17,421,113 | -60,795,749 |
| Profit Margin | -5.6% | -5.3% | -18.5% |
| EBITDA | -26,995,931 | -24,267,727 | -79,903,104 |
| Free Cash Flow | — | — | -60,969,564 |
| Rev Growth | +5.7% | +5.7% | -9.3% |
| Debt/Equity | — | — | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.16 | +0.29% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $463.66 | -0.34% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $169.91 | +0.35% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $550.07 | -0.15% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $911.56 | -0.91% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $151.28 | -3.40% | 7.7 | 20.98B |